Multiple Sclerosis - Antegren to Challenge Beta-Interferons

The Multiple Sclerosis market is led by Biogen’s Avonex, which for the first time enjoyed blockbuster revenues in 2002. However, competition is strong, especially from Serono’s Rebif, which is rapidly capturing a large portion of Biogen’s US market share. This In-Depth Analysis covers the current and future MS market, and provides key strategic recommendations for existing and potential investors.

Scope:

* Detailed coverage of the patient potential of MS across the seven major country markets, and analysis of the main unmet needs

* Global and country specific drug sales and comprehensive profiles of Avonex, Betaseron, Copaxone, Novantrone and Rebif

* Identifies strategies companies employ to maximize their MS drug revenues including reformulations, new indications, and pricing strategies

* Examines the most promising candidates in the Phase II and III R&D pipeline, including Biogen/Elan’s Antegren

Report Highlights:

Improved drug delivery methods of existing treatments is a key unmet need. Due to disappointing trial results, Datamonitor does not expect existing players to launch oral forms of their products before 2008. However, the main short-term opportunity will be launching room temperature and pre-filled pre-mixed syringes. 

The US launch of Rebif in particular was a sharp blow to Biogen, as the decision voided Avonex’s exclusivity in the US market - the first time the FDA has done this - which entitled Biogen to seven years orphan drug status. Indeed, Biogen has reported a decline in growth rates since the US launch of Rebif. 

Reasons to Purchase:

* Understand the benefits and drawbacks of current treatments for MS patients, in order to target key unmet needs 

* Enhance your sales forecasting ability and future product positioning through identification of market drivers and key existing and future competitors 

* Pinpoint hot areas of the market that are not being targeted by competitors 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a30